Table 1 Membrane modifications after hormone treatments in different breast cancer cell lines

T47-D

CON

32.4 ± 5.8

61.5 ± 8.3

59.8 ± 5.6

5.2 ± 0.8 %

P

62.3 ± 9.2*

102.2 ± 10.4*

62.3 ± 7.4

64.5 ± 5.4 % *

P+E2

78.2 ± 10.3*

124.5 ± 13.2*

58.5 ± 6.1

72.2 ± 5.7 % *

MPA

76.3 ± 14.6*

118.6 ± 12.7*

67.8 ± 8.2

69.6 ± 6.1 % *

MPA+E2

92.5 ± 12.3*

131.8 ± 12.4*

57.4 ± 6.6

81.8 ± 4.9 % *

DRSP

54.6 ± 6.7 *

87.2 ± 8.3 *

61.6 ± 8.2

60.4 ± 4.4 % *

DRSP+E2

60.3 ± 5.2 *

98.5 ± 11.6*

57.8 ± 6.7

68.1 ± 5.2 % *

NES

71.5 ± 8.6*

110.2 ± 14.4 *

61.4 ± 8.5

69.6 ± 6.5 % *

NES+E2

80.6 ± 10.5 *

127.3 ± 7.2 *

59.1 ± 5.4

73.1 ± 5.6 % *

MCF-7

CON

46.6 ± 4.7

77.8 ± 5.8

74.3 ± 6.2

6.7 ± 1.3 %

P

99.2 ± 7.4 *

132.4 ± 8.6 *

68.5 ± 4.7

70.6 ± 7.4 % *

P+E2

115.8 ± 8.3 *

140.3 ± 10.2 *

66.3 ± 5.2

68.3 ± 6.2 % *

MPA

108.4 ± 11.3 *

142.7 ± 12.5 *

60.4 ± 5.6

78.2 ± 7.8 % *

MPA+E2

123.6 ± 10.8 *

150.2 ± 14.6 *

62.5 ± 4.9

80.5 ± 7.2 % *

MDA-MB-468

CON

31.2 ± 4.4

66.8 ± 7.2

62.6 ± 5.5

5.4 ± 0.7 %

P

34.3 ± 4.1

70.5 ± 6.4

64.2 ± 5.8

4.8 ± 0.6 %

P+E2

32.5 ± 3.9

68.1 ± 5.8

61.4 ± 4.3

5.1 ± 0.4 %

MPA

36.2 ± 5.2

67.2 ± 5.5

70.5 ± 5.3

4.4 ± 0.8 %

MPA+E2

32.2 ± 4.6

63.6 ± 6.2

66.3 ± 5.6

5.2 ± 0.7 %

MDA-MB-468 (transfected with PR)

CON

34.6 ± 4.3

65.4 ± 6.8

70.4 ± 5.2

5.2 ± 0.9 %

P

66.7 ± 6.8 *

97.4 ± 8.3 *

66.3 ± 4.8

58.6 ± 6.7 % *

P+E2

72.5 ± 7.1 *

106.3 ± 10.6 *

72.5 ± 6.4

60.3 ± 6.9 % *

MPA

70.4 ± 7.4 *

102.8 ± 11.8 *

68.2 ± 5.5

60.2 ± 6.6 % *

MPA+E2

76.2 ± 8.2 *

118.5 ± 13.2 *

71.8 ± 6.8

65.8 ± 7.1 % *